Drug intelligence / Profile preview

BIVAP-COVID-19

Development stage: Preclinical
Lead developer: IMMUNEO Therapeutics
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

BIVAP-COVID-19 is a peptide-based prophylactic vaccine candidate being developed by IMMUNEO Therapeutics for the prevention of COVID-19. The vaccine is designed to present specific viral epitopes to the immune system to induce a protective immune response against the SARS-CoV-2 virus. It leverages IMMUNEO's peptide technology platform to target conserved or highly immunogenic regions of the virus, aiming to provide a focused and effective immunization strategy. The candidate is currently in the pre-clinical stage of development.

Other names: BIVAP

Targets

SARS-CoV-2

Beyond the preview

Go deeper on BIVAP-COVID-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIVAP-COVID-19.

Explore the full profile